Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing’s sarcoma treatment: A network meta-analysis
Year: 2026
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: BACKGROUND: Optimal chemotherapy for nonmetastatic Ewing's sarcoma (ES) remains undefined, with no global consensus established among the available multidrug regimens. METHODS: We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases (VIP [Chinese Scientific Journal Database], WanFang, China National Knowledge Infrastructure) up to May 2024 for randomized controlled trials (RCTs) and cohort studies comparing chemotherapy regimens for nonmetastatic ES. Risk of bias was evaluated using Cochrane tools (for RCTs) and the Newcastle-Ottawa Scale (for cohort studies). Efficacy was ranked via surface under the cumulative ranking curve (SUCRA) values for event-free survival and overall survival. RESULTS: Twelve studies (3834 patients) evaluating 9 regimens were included. The top 3 regimens for event-free survival were as follows: VDC (vincristine/doxorubicin/cyclophosphamide) + IE (ifosfamide/etoposide)(In)(intensified regimen) and VTC (vincristine, topotecan, cyclophosphamide) (SUCRA = 92.1%); VDC+IE(In) (SUCRA = 85.4%); VDC+IE(St)(standard regimen) (SUCRA = 79.2%). For overall survival, the ranking was similar. VDC alone ranked lowest in both outcomes. CONCLUSION: The VDC+IE(In)+VTC combination may exhibit superior efficacy among the 9 chemotherapy regimens for nonmetastatic ES, necessitating further validation through RCTs with larger sample sizes.
Source: Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,950
OpenAlex ID: W7226017264
